Get started
ELI LILLY AND COELI LILLY AND COELI LILLY AND CO

ELI LILLY AND CO

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

LLY trade ideas

Loss in weight loss Drugs GLP1 Drug producers started 2024 with very strong momentum with Lilly touching nearly a market cap of 1T USD. But since then, the GLP1 manufactures have lost a lot of momentum. Novo Nordisk is at 52 weeks low as shown by the red line. Eli Lilly stock chart also showing bearish engulfing candle. The 20-Day, 50-Day and 100-Day are almost below the 200 Day SMA showing bearish divergence. IN the short to medium term the Price trend looks bearish unless there is a positive catalyst for the stock.
NYSE:LLYShort
by RabishankarBiswal
1
LLY: Bearish Trend and Short-term Risk🔥 LucanInvstor's Strategy: 🩸 Short: Below $738.05, targeting $720 and $700. The MACD remains negative, and the price is below both the 9-day and 200-day EMAs, signaling a continued downtrend in the short term. 🩸 Long: Above $824.17, targeting $830 and $850. A break above resistance could resume the bullish trend, but caution is needed due to current bearish pressures. 🔥 LucanInvstor's Commands: 🩸 Resistance: $824.17 — A key resistance level; breaking above this could trigger further upside. 🩸 Support: $738.05 — A critical support level; a breakdown below this could lead to further declines. Eli Lilly is under bearish pressure in the short term, with increasing selling volume and negative MACD momentum. A breakdown below support could lead to a further pullback, while a breakout above resistance could signal a reversal of the current trend. 👑 "In the face of adversity, clarity in action drives success."
NYSE:LLY
by LucanInvestor
1
symmetri triangel Eli Lilly has formed a symmetrical triangle after falling from an ascending trend. The hypothesis is supported by decreasing volume towards the apex. Ideally, the breakout should occur 2/3 of the way into the triangle. That is not the case here. Now we are close to the apex, so a breakout must be imminent. It is difficult to predict the direction of the breakout with a symmetrical triangle, even though the upper boundary has been tested the most. Be mindful of false breakouts – a true breakout should occur with high volume. Disclaimer: I have a position in Eli Lilly.
NYSE:LLY
by scorpiris
1
Halftime Report: LLY Up From Here? Hold for better PriceWe've been watching LLY after Open this morning allowed it to bounce up to $783.63. It has since settled on the 50% Retracement on the 5 Minute, which we were looking for it to break down back to at least the $765-$766 Price Range, looking to get in around $765.45specifically. With a Price Target $775 (Short-Term Trade Target) on the rebound and retest. We're looking at a stop around $761.97 to be safe in case it comes down hard and surpasses our entry. On a longer-time frame, we're looking for potential a $780.65 - $785 retest. Stay tuned by connecting at the website in our signature! We deliver this and more financial tools to make life that much easier on You! - @MyMIWallet #MyMIWallet
NYSE:LLYLong
by MyMIWallet
LLY 1H Swing Long Aggressive Trend TradeAggressive Trend Trade - short impulse + volumed TE / T1 + support level + biggest volume Sp + weak test + first bullish bar close entry Calculated affordable stop limit 1 to 2 R/R take profit Daily Context "+ long impulse + 1/2 correction - expanding T2 + support level + volumed manipulation" Monthly Context "+ long impulse + 1/2 correction + T2 level + support level - biggest volume manipulation" Yearly Context "+ long impulse - neutral zone"
NYSE:LLYLong
by MishaSuvorov
Why Buy LLY?A textbook spike trade... that's why! Every morning the stock market open gives us opening volatility spikes on the first 30 minute bar. Most are noise but when that rare one comes along that fits my rules AND has multiple matching confluences... it's time to "Strike at the Spike!" This setup has going for it: At a 50% Retracement of the recent trend (from November 18 - December 4) At the top of a Gap Level At the Volume Profile Point-of-Control for the last year of price action (see below) With a Spike that my indicator shows >80% ATR Clearance I consider the baseline for a trade; this one is 150% so it definitely fits the rules. I would take a spike if there were only 2 of those matching levels above. Targeting the local high for the first take profit at 834. Here is the Daily chart for just how key this level is: Full disclosure: NYSE:LLY is and has been one of my biggest holdings; having owned the stock for over a decade.
NYSE:LLYLong
by norok
Eli Lilly: Is the Uptrend Fading?Eli Lilly has been one of the best-performing large-cap stocks in recent years. But now it may be showing signs of stalling. The first pattern on today’s chart is the bearish price gap on October 30 after earnings and revenue missed estimates. LLY has remained below the gap since, which may suggest that new resistance has been established. Second, the recent bounce pulled stochastics into overbought territory. Third, the drugmaker has remained below its 200-day simple moving average (SMA). The 50-day SMA is also nearing a potential “death cross” below its 200-day SMA. Finally, consider that LLY is up 578 percent in the five-year period ended last month. That’s the fourth-biggest gain in the S&P 500 over the period, according to TradeStation Data. (Nvidia, Tesla and Builders FirstSource have risen more.) Given the magnitude of its run, many investors could be sitting on significant long-term gains. Could that open the door to profit taking? TradeStation has, for decades, advanced the trading industry, providing access to stocks, options and futures. If you're born to trade, we could be for you. See our Overview for more. Past performance, whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. There is a possibility that you may sustain a loss equal to or greater than your entire investment regardless of which asset class you trade (equities, options or futures); therefore, you should not invest or risk money that you cannot afford to lose. Online trading is not suitable for all investors. View the document titled Characteristics and Risks of Standardized Options at www.TradeStation.com . Before trading any asset class, customers must read the relevant risk disclosure statements on www.TradeStation.com . System access and trade placement and execution may be delayed or fail due to market volatility and volume, quote delays, system and software errors, Internet traffic, outages and other factors. Securities and futures trading is offered to self-directed customers by TradeStation Securities, Inc., a broker-dealer registered with the Securities and Exchange Commission and a futures commission merchant licensed with the Commodity Futures Trading Commission). TradeStation Securities is a member of the Financial Industry Regulatory Authority, the National Futures Association, and a number of exchanges. TradeStation Securities, Inc. and TradeStation Technologies, Inc. are each wholly owned subsidiaries of TradeStation Group, Inc., both operating, and providing products and services, under the TradeStation brand and trademark. When applying for, or purchasing, accounts, subscriptions, products and services, it is important that you know which company you will be dealing with. Visit www.TradeStation.com for further important information explaining what this means.
NYSE:LLY
by TradeStation
2
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention. The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success. Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
NYSE:LLYLong
by signalmastermind
Eli Lilly is facing problems after the earnings presentation🔴 Eli Lilly is facing problems after the earnings presentation NYSE:LLY has broken an especially important support and is now in free fall. Avoid buying it now. The break also activates the bearish double top and that means that the $550 is the target of the pattern. If you look close to the chart, the volume appears in the $550-600 area, which is very similar to the double top target price. $725 is the last support before a free fall to under $600.
NYSE:LLYShort
by TopChartPatterns
$LLY Long-Term BuyHealthcare could possibly be the next rotation coming out of this tech bull run. Using the Trade Jeanie (Jeanius Screener/Indicator), I was able to see the current technical buy signals happening on NYSE:LLY : Inside a HTF fair value gap (3M timeframe) Took out an untested low (liquidity) The Jeanius Indicator shows green 'Combo' labels every time this same combination of signals happened The Jeanius Screener lets me filter my favorite tickers to see which ones are currently taking out untested lows or liquidity
NYSE:LLYLong
by jeanius_tech
ELI LILLY has at least +50% upside from here.Eli Lilly (LLY) has been trading within a 5-year Channel Up and last week closed below its 1W MA50 (blue trend-line) for the first time since the week of March 06 2023. Despite the bearish pressure of this Bearish Leg since July 15 2024, that last 1W MA50 closing was the previous Higher Low at the bottom of the Channel Up. The 1W RSI is on a similar level (just below 40.00) with all previous 4 major bottoms and the common characteristic of all was that the stock broke below the 1W MA50 but managed to keep clear and hold the 1W MA100 (green trend-line), practically the most important Support level of the market. If you want a confirmed buy entry, you might want to wait for yet another Bullish Cross on the 1W MACD (as it happened on all previous bottoms), otherwise this buy opportunity is good to go for at least +58% from the bottom (minimum rise among those 4 Bullish Legs). Our Target is $1135. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLYLong
by TradingShot
5
LLY bounce to $822 (+dividend)MODs have suggested that I provide more detail about the picks I make. Sorry. I'm not as verbose as y'all, and I don't like things to be complicated. My trading plan is very simple. I buy or sell at top & bottom of parallel channels. I confirm when price hits Fibonacci levels. So... Here's why I'm picking this symbol to do the thing. Price at bottom channels (period 100 52 39 & 26) Stochastic Momentum Index (SMI) at oversold level VBSM is spiked negative Price at or near 1.618 Fibonacci level In at $752.25 Target is $822 or channel top Stop loss is $746
NYSE:LLYLong
by chancethepug
5